In brief
Vaccine elicitation of tier-2 HIV-1 neutralizing antibodies in humans has been a long-sought goal. Wang et al. isolate and determine structures of two antibodies from a clinical trial of a prefusion-closed HIV-1 envelope trimer. These antibodies target the fusion-peptide site of vulnerability, form a reproducible class, and neutralize the tier-2 HIV-1 strain BG505.